European journal of pain : EJP
-
Randomized Controlled Trial Comparative Study
Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation. ⋯ Gastrointestinal symptoms of cancer pain patients undergoing an opioid therapy are related to multifactorial causes. Transdermal opioids showed no benefit over oral controlled-release hydromorphone with regard to gastrointestinal symptoms. The conversion ratios for transdermal fentanyl, transdermal buprenorphine, and oral hydromorphone did not accord to the literature, because of differing occurrences of opioid tolerance after long-term therapy.
-
Randomized Controlled Trial
Temporal summation of pressure pain during muscle hyperalgesia evoked by nerve growth factor and eccentric contractions.
Nerve growth factor (NGF) has a key role in the generation and potentiation of pain. Its centrally sensitizing effects may facilitate pain responses to noxious stimulus. This study assessed (1) the influence of NGF on delayed onset muscle soreness (DOMS) in shoulder muscles; and (2) the temporal summation of pressure pain during hyperalgesia induced by NGF and DOMS. ⋯ The NGF injected side had higher pain ratings during temporal summation at 1s ISI compared with the contralateral side 24h after injections. Intramuscular administration of NGF intensified the DOMS responses, evoking facilitated temporal summation. Central as well as peripheral sensitization mechanisms may play a role in the facilitation.